The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Letter to the Editor

The Role of Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 in Predicting Response to Chemotherapy in Patients with Advanced Nonsmall Cell Lung Cancer

Authors: Aziz Yazar, MD, Hilal Soydinc, PhD, Esra Ertan, MD, Vildan Yasasever, PhD, Faruk Tas, MD

Abstract

To the Editor:


The resistance to chemotherapy is a very important clinical issue in advanced stage nonsmall cell lung cancer (NSCLC), and because of this resistance, some patients unnecessarily receive chemotherapy despite adverse toxicities.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29–42.
 
2.Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5:149–153.
 
3.Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum matrix metallo protienase levels with lung cancer metastasis and response to therapy. Cancer Res 1992; 52:4548–4549.
 
4.Tas F, Duranyildiz D, Oguz H, et al. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 2006;24:576–580.
 
5.Lissoni P, Rovelli F, Malugani F, et al. Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers 2003;18:152–155.